Aim: To use iontophoresis in conjunction with triamcinolone acetonide (TA) in ameliorating the symptoms of oral submucous fibrosis (OSMF) and further to evaluate the levels of the salivary lactate dehydrogenase (LDH) enzyme pre- and post-intervention. Materials and methods: Forty-five OSMF patients were divided equally into 3 groups with 15 patients each. Salivary LDH levels of these 45 OSMF patients were assessed and compared with those of healthy controls. Comparison of pre- and post-treatment salivary LDH levels was also done. Results: The salivary LDH level of OSMF patients (517.63 ± 150.80 U/L) was higher than that of the controls (141.70 ± 49.98 U/L). All the patients showed a significant (p > 0.001) decrease in salivary LDH levels following treatment, with a maximum reduction seen in group III. Conclusion: Group III had shown better results than group I and II with a maximum decline in LDH levels in group III. Clinical significance: In OSMF, TA, an intermediate-acting steroid, is commonly used by practitioners in the form of topical gels and intralesional injections; however, the drawback with the topical application is the wash-away of the drug through saliva while intralesional injections have the disadvantage of pain and discomfort due to multiple punctures, invasiveness, less patient acceptability, and chances of post-treatment fibrosis. To overcome such barriers, “iontophoresis”, an electromedical method of transmucosal drug delivery to a specific anatomical site, could serve as a surrogate means that does not require venipuncture (an invasive technique). Estimation of LDH levels in saliva as a manifestation of cellular necrosis and oxidative stress can serve as a precise indicator of lesions disturbing the integrity of the oral mucosa.